Study Of Remission In Patients Treated For Generalized Anxiety Disorder

Completed

• Conditions: Anxiety Disorders
• Interventions: Other: remission prevalence of generalized anxiety disorder

• Registration Number: NCT01788553
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care. Factors that may influence remission such as disease history and severity of the anxiety disorder, the type of treatment, the presence of co-morbid depression or anxiety disorder as well as socio-demographic factors will also be evaluated. The study will also assess patient functioning and compare functioning in patients who do and do not achieve remission.

Detailed Description

The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care. Factors that may influence remission such as disease history and severity of the anxiety disorder, the type of treatment, the presence of co-morbid depression or anxiety disorder as well as socio-demographic factors will also be evaluated. The study will also assess patient functioning and compare functioning in patients who do and do not achieve remission.

The objectives of the study are:

Primary: To determine the prevalence of remission in patients treated for generalized anxiety disorder in primary care and specialized care. Secondary: To determine patient functioning and work loss days and compare these in patients who do or do not achieve remission. To determine the effect of disease factors on remission rate such as disease history, duration, severity, co-morbidity with depression or other anxiety disorders. To determine the effect of treatment factors on remission rate such as setting, type of treatment, duration and adherence. To determine the effect of socio-demographic factors on remission rate such as gender, age, region (language), marital status, educational level and employment status.

This will be a cross-sectional observational study looking at the point prevalence of remission in treated patients with generalized anxiety disorder in general practice and specialized care in Belgium. General practitioners and psychiatrists will assess remission rates in patients treated for generalized anxiety disorder during 1 routine visit of these patients.

The participating physicians will have 3 months to evaluate remission at a routine visit in 5 to 10 patients that have been treated for generalized anxiety disorder since at least 3 months

Study Timeline

• Study Start: 2006-03
• Primary Completion: 2006-03
• Study Completion: 2007-03
• Study First Submitted: 2009-07-06
• Study First Submitted QC: 2013-02-08
• Study First Posted: 2013-02-11
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-28
• Last Update Posted: 2022-05-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 750

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients with generalized anxiety disorder	remission prevalence of generalized anxiety disorder	-

Primary Outcome Measures

Name	Time	Method
remission of generalized anxiety disorder	5 months

Secondary Outcome Measures

Name	Time	Method
determine the effect of disease and treatment factors on remission rates	5 months

Trial Locations

Locations (1)

Pfizer Inc.; 🇧🇪 Brussel, Belgium